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Introduction: Lung disease remains the main cause of morbidity and mortality in patients with
Cystic Fibrosis (CF). To detect lung disease before clinical symptoms become apparent, sensi-
tive tools are essential. Spirometry is used for monitoring, but the FEV1 remains frequently
normal throughout childhood. The Lung Clearance Index (LCI) calculated from Multiple Breath
Washout (MBW) was introduced at the CF centre Innsbruck in 2007 for assessing ventilation in-
homogeneity in patients with mild lung disease.
We hypothesized that LCIs in 2007 are of prognostic value for the presence or absence of
structural lung changes in later years.
Methods: Between 2007 and 2010 MBW, spirometry and ultra-low-dose HR-CT were prospec-
tively tracked in 36 patients (6e53 years) with a mean FEV1 80% predicted in 2007.
Results: At study start the majority of patients had abnormal CT scores and LCI results. While
CT and spirometry remained largely stable throughout the study, LCI results slightly improved
but still correlated with CT scores in 2010. LCI results in 2007 correlated with CT scores in 2010
while FEV1 did not. In 86% the LCI value in 2007 was indicative for the presence or absence of
structural lung changes in 2010.49 281 104 1170.
homine.de (S.I. Fuchs).
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866 S.I. Fuchs et al.Conclusion: The LCI is a sensitive tool for detecting and tracking pulmonary changes. Extended
structural changes are unlikely if the LCI is normal. The LCI has the potential to be used for
monitoring the progression of early CF lung disease and assessing the effect of treatment in
both clinical care and research settings.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Following considerably intensified treatment strategies
over the last decades, life expectancy and quality of life
have been greatly improved for patients with Cystic
Fibrosis (CF). However, lung disease remains the main
cause of morbidity and mortality [1,2]. Detecting early
signs of CF lung disease and, where appropriate, earlier
onset of treatment may further improve prognosis and
outcome [3].
Thus, sensitive methods for monitoring early lung dis-
ease in CF are required for both, clinical and research
purposes, e.g. the development and evaluation of new
treatment strategies that are appropriate to halt progres-
sion before irreversible lung damage has occurred [4,5].
Development of bronchiectasis is the most important
component of CF lung disease. Thus, computed chest to-
mography (CT) is the reference method for detecting early
and advanced bronchiectasis [6]. CT of the lungs has
received increasing attention in recent years particularly
for assessing early stages of CF lung disease that are not
detectable by conventional spirometry [7e9]. However,
there remains concern regarding repeated radiation expo-
sure from routine CT, particularly with respect to the
increasing life expectancy of patients with CF [10,11].
Therefore in most countries repeated routine CT is not
commonly performed for monitoring. While international
efforts for developing a standardized low-dose protocol are
still ongoing, in Innsbruck yearly CTs in patients with CF
have been performed using an internal ultra-low-dose
protocol and a modified Bhalla score for interpretation
since 2001.
Conventional lung function tests are routinely per-
formed at least 4 times a year from approximately age 4e5
to assess extent and progression of CF lung disease although
the majority of paediatric patients present normal results
with a relatively large inter- and intra-individual variability
throughout childhood. Most commonly, the forced expira-
tory volume in one second (FEV1) is reported for clinical and
research purposes. However, there is increasing scientific
evidence that FEV1 has a low sensitivity for detecting early
pulmonary disease, since studies demonstrated structural
pulmonary changes in patients with normal spirometry
[6,8,12]. For early intervention studies, the use of spiro-
metric parameters as outcome parameters would require
unrealistically large sample sizes and long study durations
because of its low sensitivity and high variability.
Inert gas Multiple Breath Washout (MBW) for assessing
ventilation inhomogeneity (VI) is a non-invasive and safe
lung function test that has been shown to be sensitive for
detecting early pulmonary changes in CF [13e16]. Several
indices of ventilation inhomogeneity, such as the LungClearance Index (LCI) can be calculated from the
washout curves documenting the presence and quanti-
fying the extent of VI. The LCI reflects overall VI within
the peripheral and communicating zones of the lungs
[17]. In cross-sectional studies the majority of paediatric
patients with CF had abnormal LCI results, even in the
presence of a normal FEV1 [13e15,18,19]. In three recent
studies the LCI was used as outcome parameter for
assessing the effect of inhaled hypertonic saline and
Dornase-alpha in young patients with CF [20e22].
Furthermore, LCI had a high sensitivity to detect
abnormal imaging results in cross-sectional studies.
However this was more obvious in school-age children
than in infants [19,23e25]. Implementing longitudinal
measurements of LCI into routine lung function testing in
CF centres may thus be of clinical and prognostic value
and may contribute to reduce radiation exposure,
particularly in young patients with CF.
Currently, little is known about the longitudinal course
of the LCI and its prognostic value for patients with CF.
There is one retrospective [26] and one prospective [3]
longitudinal study, tracking spirometry and MBW in paedi-
atric patients beyond infancy. From the prospective data
the authors concluded that an abnormal LCI in preschool
age predicts any lung function abnormalities in early school
age and that a normal LCI in preschool age usually remains
normal until school age. To date there are no studies which
prospectively track MBW in comparison to CT. At the CF
centre in Innsbruck, ultra-low-dose chest CT is performed
on a yearly basis in all patients since 2001 and yearly
measurement of the LCI was introduced in 2007.
We hypothesized that the LCI would be as sensitive as
chest CT in detecting pulmonary changes. In the present
study, we prospectively evaluated MBW, spirometry and
chest CT over a period of three years in a relatively healthy
group of patients with CF who had a normal FEV1 at study
start.
The aim was 1) to investigate the longitudinal course of
the LCI in comparison to spirometry and CT and 2) to
examine whether LCI results sampled in 2007 are of prog-
nostic value for structural lung abnormalities diagnosed
from CT in 2010.
Methods
Study design
This is a prospective, longitudinal observational study in a
group of school children, adolescents and few adults with
mild CF lung disease. During the study period of three years
four test occasions at intervals of approximately one year
were aimed pro participant.
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Measurements were carried out between 2007 and 2010 at
the CF centre of the Medical University Innsbruck located at
the Department of Paediatrics. Outpatients in a stable
clinical state were studied during one of their quarterly
routine visits to the CF centre. Test occasions were post-
poned in patients with acute exacerbations. The routine
diagnostic workup for CF patients was performed as usual.
A reduced clinical status, detection of pathogens in routine
throat swaps or observation of a deteriorated lung function
was followed by intensification of causal or symptomatic
treatment.
A quality management system for diagnostic and
therapeutic policies is in place at the CF centre that had
been certified according to DIN EN ISO 9001:2008.
Treatment procedures are in accordance with the stan-
dards of care reported by the European Cystic Fibrosis
Society. Prophylactic antibiotics are not used routinely. A
protocol of early eradication of Pseudomonas aeruginosa
infection has been installed. Patients are on standard
mucociliary clearance therapy. Starting in 2007, the
majority of patients inhaled hypertonic saline for pre-
ventive purposes.
Newborn screening (NBS) was implemented in Tyrol in
1992.Participants
The CF patient database at the Medical University Inns-
bruck which contains information on 160 patients was
screened to identify patients who had an annual average
FEV1 >80% of the predicted normal value (at a minimum of
4 measurements) during the preceding year and a stable
clinical status. The study cohort was selected from all pa-
tients who were scheduled for a routine visit between May
and August 2007.
The study was approved by the local ethics committee.
Parental informed written consent and patient assent was
obtained prior to the measurements.Protocol
At any test occasion lung function testing was per-
formed after a session of standard physiotherapy. De-
mographic and clinical data were documented
subsequently.
Each subject started assessment of lung function with
2e3 technically acceptable MBW measurements. For MBW
patients were in a sitting position wearing a nose clip,
breathing through a mouthpiece while watching a video.
Spirometry was then performed according to ATS/ERS
recommendations [27,28].
Longitudinal assessment of lung function was performed
at intervals of one year during the patients’ routine visits in
the CF centre.
Yearly CT scans were timed as close as possible to the
test occasions for assessment of lung function but for
ethical reasons also in accordance to the patient’s indi-
vidual protocol.Measurements
Spirometry
Spirometry was performed according to ATS/ERS standards
[27,28] using a Master Screen Bodyplethysmograph (Erich
Jaeger, Germany).
Primary outcome of spirometry was the forced expira-
tory volume in one second (FEV1). Forced expiratory flow at
75% expired volume (FEF75) was calculated as secondary
outcome and further parameters such as forced vital ca-
pacity (FVC) were calculated for quality control purposes
only.
Results were expressed as Z-scores (SD) according to the
reference equations by Quanjer et al. with a lower limit of
normal defined as 1.96 z-scores [29].
Ultra-low-dose chest computed tomography
The monitoring programme at the CF centre in Innsbruck
includes yearly ultra-low-dose volumetric thin-section
multi-detector computer tomography scanning (MDCT) in
all CF patients. Axial images were obtained in a supine
position during a single deep inspiration hold and covered
the entire lung parenchyma from the base to the apex of
the lung using a 16- or 64-sclice CT scanner (GE Lightspeed
16 or Lightspeed Volume CT, Milwaukee, USA) with the
following settings: 120 keV, 10 mA, rotation time 0.8 s,
1.25 mm sections, 1.25 mm interval. The displayed dose
length product (DLP) ranged from 8.50 to 22.52 mGy*cm,
and the calculated estimation of mean effective dose
generated by this protocol yielded 0.15 mSv (range:
0.12e0.33 mSv) [30]. Scans were scored by two indepen-
dent experienced radiologists of the Department of Radi-
ology who were blinded to the patients’ identity, to their
clinical status and to the results of lung function tests.
A modified Bhalla score is commonly used for clinical
interpretation of results at the CF Centre Innsbruck. The
modified Bhalla score covers nine items that can be
weighted with 0e3 or 0e2 points respectively: 1) severity
(0e3 points), 2) expansion (0e3 points) and 3) peripheral
expansion (0e3 points) of bronchiectasis, 4) airway wall
thickening (0e3 points), 5) mucus plugging (0e3 points), 6)
presence of bullae (0e3 points), 7) presence of emphysema
(0e2 points), 8) presence of abscesses (0e3 points) and 9)
presence of consolidations (0e2 points) [31,32].
A score of 25 points corresponds to a normal lung. The
lower limit of normal was defined as 24/25 points [19].
MBW
The ultrasonic technology and the side stream ultrasonic
flow sensor (USFS) prototype system (EasyOne Pro, MBW
Module, ndd Medizintechnik AG, Zurich, Switzerland) was
described previously [33]. Briefly, the system consists of a
mainstream ultrasonic transducer for flow sampling, a side
stream ultrasonic transducer for temperature independent
sampling of the molar mass (MMss) and a side stream
infrared CO2 analyzer (DUET ETCO2 Module, Welch Allyn
OEM Technologies, Beaverton). The gas bias flow system
that provides valve-controlled tracer gas delivery contain-
ing 4% sulfurhexafluoride (SF6), 21% oxygen and balanced
nitrogen (Linde AG, Germany) is automatically removed
during the washout phase, thus reducing the apparatus
dead space to a minimum. Calibration of the system and
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formed as described previously [34,35].
To start a measurement, subjects breathed quietly
through the mouthpiece. The bias flow is automatically
switched to the tracer gas at end expiration. Equilibrium is
defined as a visually stable plateau of the MMss signal. The
bias flow is then switched back into room air for washout,
which is finished when the SF6 concentration falls below
2.5% (1/40) of the starting level.
FRC was calculated from the cumulative volume (CEV) of
expired SF6 divided by the difference between end-tidal gas
concentration at the start and end of the washout. LCI was
calculated as the CEV divided by the FRC. Analysis has been
described in detail previously and was performed according
to recommendations published recently [17]. The upper
limit of normal (group mean þ 2SD) for the LCI (7) was
derived from a healthy population that was investigated
with the same method, test procedure, equipment and by
the same observers [34]. LCI results >8 and 9 were
defined as moderately and >9 and as markedly increased.
In patients with CF, where manifestation of lung disease
is likely to be present, a time frame of 30e40 min is
required for a complete MBW test including 2e3 single
washouts.
WBreathª software (version 3.37.1.0) was used for data
acquisition, storage and analysis.
Other tests
Additional information on CF patients concerning genotype,
microbiology, pancreas function and type of CF manifes-
tation was obtained from in and outpatient records and
from the CF patient database.Table 1 Patient flow and availability of data.
2007
(n Z 36)
2008
(n Z 36)
2009
(n Z 36)
2010
(n Z 36)
Demographics 36 36 35
(n Z 1
missing)
35
(n Z 1
missing)
Spirometry 36 34
(n Z 2
missing)
35
(n Z 1
missing)
35
(n Z 1
missing)
MBW 36 31
(n Z 3
invalid,
n Z 2 not
done)
31
(n Z 5
invalid)
32
(n Z 3
invalid,
n Z 1 not
done)
CT (Bhalla
score)
36 36 26
(n Z 10
not done)
36Statistics
Group data for age, weight, height, BMI, FEV1-z, FEV75-z
and CT are reported as mean and standard deviation (SD).
Individual data for the LCI are reported as the mean
(standard deviation, SD) of 2e3 technically acceptable
measurements within one test occasion for each subject.
Group data are then expressed as mean (SD). The intra
individual coefficient of variation (CV[%] Z (SD/mean)
*100) was calculated to assess the within-test repeat-
ability of the LCI at any test occasion for quality control
purposes.
LCI, FEV1-z, FEV75-z and CT were tracked between 2007
and 2010 using paired t-tests for calculation of mean dif-
ferences between the test occasions, 95%confidence in-
tervals and p-values.
Pearson correlations were used to compare the CT with
LCI and FEV1 results.
Furthermore the individual LCI change between 2007
and 2010 was compared to the 95% confidence interval
(2.5th to 97.5th centiles) [3] derived from our previous
studies on assessment of the within subject variability of
the LCI in healthy controls [34]. For this study same
method, test procedure and equipment were used.
Based on these limits, LCI results in 2010 were classified
as improved, unchanged and deteriorated.
The statistical package used was SPSS version 20.0 for
Windows.Results
NZ 36 patients with a FEV1-z > 2 at the first test occasion
in 2007 and at least two further documented test occasions
including assessment of lung function and CT were included
into final analysis. All participants were in a stable clinical
status during the test occasions.
Patient flowand availability of data is presented inTable 1.
The median interval (range) between performance of
lung function and CT was 33.5 (243 to 173) days in 2007
and 0.0 (27 to 202) days in 2010. In 2010 the majority of
patients performed lung function and CT on the same day
and 26/35 (72%) completed data collection within  3 days.
Patient characteristics at study start are listed in
Table 2. The course of demographic data between 2007 and
2010 is summarised in Table 3.
Outcome data
Repeated MBW measurements were successfully imple-
mented into routine quarterly visits at the CF centre
Innsbruck. Separate test occasions at intervals of approx-
imately one year were feasible and well tolerated.
Spirometry
Group means of spirometry for all test occasions are sum-
marised in Table 4. In accordance with the inclusion
criteria, all patients had a normal FEV1-z in 2007 that
remained normal in 2010 apart from 3 individuals (8.6%)
whose FEV1-z was 2.16, 2.2 and 2.7 in 2010. Mean
difference of FEV1-z between 2007 and 2010 was 0.286
(p Z 0.069, 95% CI 0.023; 0.60).
34 patients (94.4%) started with a normal FEF75-z in 2007
that remained normal in 32 (91.4%) in 2010. Abnormal re-
sults of FEF75-z in 2007 and 2010 ranged between 2.1 and
2.9. The mean difference of FEF75-z between 2007 and
2010 was 0.053 (p Z 0.752, 95% CI -0.391; 0.285).
Ultra-low-dose chest computed tomography
Group means of modified Bhalla scores for each test occa-
sion are summarised in Table 4. Mean difference of the
Table 2 Patient characteristics at study start 2007.
2007 (n Z 36)
Males:females 21:15
CFTR genotype
F508del homozygous 21
F508del heterozygous 14
Two other mutations 1
P. aeruginosa positive 11
Pancreatic insufficiency 33
Type of CF manifestation
Screening 14
Gastrointestinal symptoms 10
Pulmonary symptoms 4
Meconium ileus 4
Sibling 4
Tracking LCI and CT in mild CF lung disease 869modified Bhalla score between 2007 and 2010 was 0.09
points (p Z 0.692, 95% CI 0.522;0.350).
In both years, 2007 and 2010, 29 out of 36 patients (81%)
had a score below the lower limit of normal (<24 Points).
Between 2007 and 2010 no one switched from an abnormal
score to a normal score or vice versa: Scores in 20 patients
(55.5%) remained stable, deteriorated in 5 patients (14.0%)
and improved in 11 patients (30.5%). The extent of indi-
vidual changes was distributed as follows: 2 patients with
1 point deterioration, 2 patients with 2 points deterio-
ration, 1 patient with 5 points deterioration, 8 patients
with þ1 point improvement and 3 patients withþ2 points
improvement.
MBW
Group means of MBW for all test occasions are summarised
in Table 4. The intra individual within test repeatability (CV
%) at each test occasion was 7.0, 5.9, 5.0 and 6.0 for the
FRC, and 7.0, 6.5, 6.1 and 5.4 for the LCI.
From 2007 to 2010, mean LCI improved (i.e. decreased)
by 0.726 (p Z 0.001, 95% CI 0.318; 1.135).
83% (30 out of 36) of the patients had abnormal LCI re-
sults in 2007 while 53% (17 out of 32) presented abnormal
LCI results in 2010.
32 paired LCI values measured in 2007 and 2010 were
available for comparing individual changes in LCI with the
2.5th to 97.5th centiles derived from healthy controls
(0.017e0.348) [34]. Compared to these limits, in 22 pa-
tients (69%) LCI significantly improved after three years, 6Table 3 Demographic data 2007e2010.
2007 2008 2009 2010
Median age
(range)
[yrs]
13.9 (6.3
e53.1)
14.9 (7.1
e53.8)
16.1 (8.2
e54.9)
16.9 (9.1
e56.0)
Sex (m/f) 21/15 21/15 21/15 21/15
Mean weight
(sd) [kg]
44.1 (16.9) 48.1 (16.7) 51.4 (15.9) 53.2 (15.5)
Mean height
(sd) [cm]
151.0
(20.0)
154.2
(18.2)
157.6
(16.4)
159.4
(14.7)
BMI (sd) 18.8 (3.5) 19.5 (3.7) 20.1 (3.6) 20.4 (3.7)(19%) showed a deterioration and 4 (12%) had stable LCI
results.
6 out of 36 patients (17%) started with a normal LCI <7 in
2007. All of these remained normal during the study. Mean
intra individual change (SD) between 2007 and 2010 was
only 0.01 (0.65) (Fig. 1a).
22 out of 36 patients (61%) started with a moderately
increased LCI between >7 and <9. The LCI improved in 77%
(n Z 17) while deterioration was observed in 23% (n Z 5)
until 2010. The mean intra individual change (SD) between
2007 and 2010 was 0.55 (1.13) and was thus larger than in
patients with a normal LCI at study start. Nearly 50% of this
subgroup switched from abnormal to normal LCI results
until the end of the study (Fig. 1b).
8 out of 36 patients (22%) started with markedly
increased LCIs >9. All of these improved stepwise during
the study. The mean intra individual change (SD) between
2007 and 2010 was 2.00 (0.54) and was thus considerably
larger than in patients with a normal or moderately
increased LCI at study start. 5/8 patients in this subgroup
ended up with only slightly increased LCI <8 (Fig. 1c).
Prognostic value of lung function and CT
The LCI and Bhalla score correlated in 2007 (p < 0.001,
r Z 0.565) and in 2010 (p Z 0.001, r Z 0.547), while
Bhalla score and FEV1-z did not (p Z 0.240, r Z 0.201 and
p Z 0.498, r Z 0.118 respectively).
Furthermore LCI in 2007 correlated with CT-scores in
2010 (p < 0.001, rZ 0.554) (Fig. 2a), while FEV1-z did not
(p Z 0.207, r Z 0.215) (Fig. 2b). Correlation of changes
between 2007 and 2010 in CT scores and in LCI results failed
significance (p < 0.069, r Z 0.331). However, closest
correlation was observed when comparing CT-scores 2007
and 2010 (p < 0.001, r Z 0.933) (Fig. 2c).
4 out of 6 patients with a normal LCI in 2007 had a
normal CT score in 2010 and 27 out of 30 patients with an
abnormal LCI in 2007 had an abnormal CT score in 2010.
Therefore in 86% the LCI in 2007 was indicative for the
presence or absence of structural changes seen on CT in
2010.
However, 2 out of 6 patients with a normal LCI in 2007
had an abnormal CT score (both 22 points) in 2010.
Furthermore 3 out of 30 patients with an abnormal LCI in
2007 had a normal CT score in 2010 indicating presence of
VI that was not detectable by the CT score. In contrast 29
out of 36 patients with a normal FEV1-z in 2007 (81%) had
abnormal CT scores in 2010 that ranged between 23 and 13
points.
Discussion
This is the first reported study tracking MBW, spirometry
and chest CT over a period of 3 years in a relatively healthy
CF population including mainly school children and ado-
lescents, but also few adults.
Yearly MBW measurements were successfully imple-
mented into routine visits at the CF Centre Innsbruck, were
feasible and well tolerated.
Our study confirms that the LCI is more sensitive than
FEV1 for detecting and tracking early pulmonary changes in
Table 4 Group means of lung function and CT between 2007 and 2010.
2007 2008 2009 2010
FRC (sd) [L] 1.82 (0.87) 1.85 (0.76) 1.83 (0.72) 1.92 (0.75)
LCI (sd) 8.0 (1.35) 7.7 (1.48) 7.49 (1.22) 7.2 (1.21)
FEV1-z (sd) 0.26 (0.97) 0.24 (1.32) 0.20 (1.22) 0.51 (1.12)
FEF75-z (sd) 0.38 (1.09) 0.13 (1.46) 0.37 (1.49) 0.25 (1.17)
Bhalla score (sd) 20.1 (3.46) 20.25 (3.40) 20.54 (3.40) 20.14 (3.34)
870 S.I. Fuchs et al.CF. Longitudinal application of MBW demonstrates that the
LCI is of prognostic value for the presence or absence of
structural lung changes observed in CT scans in later years.
At study start the majority of patients presented
abnormal CT scores and LCI results in the presence of a
normal FEV1. Surprisingly, while CT and spirometry
remained largely stable during the entire study period, LCI
results slightly improved over the study period but still
correlated with CT scores until 2010. LCI results in 2007
correlated with CT scores in 2010 (Fig. 2a) while FEV1 did
not (Fig. 2b). In 86% the LCI value in 2007 was indicative for
the presence or absence of structural lung changes in 2010.
Spirometry
As expected in this clinically stable study population with
only mild lung disease, group data as well as the majority of
individual FEV1 and FEF75 results remained normal between
2007 and 2010 (Table 4).
In 2010 an abnormal FEV1 was observed in only three
patients who started with a normal FEV1, normal FEF75,
decreased CT scores between 16 and 22 points and
moderately increased LCIs up to 9 in 2007.
FEF75, often considered as a parameter to assess pe-
ripheral airway function, was not any better with only 3
patients having abnormal values.
These few cases again support previous observations
that spirometry is not sensitive for detecting early CF
related VI, delays diagnosis when used without other
diagnostic tools such as CT or MBW and is thus not helpful
for detecting and monitoring manifestation of CF lung dis-
ease [6,8,12].
Ultra-low-dose chest computed tomography
The majority of this clinically stable study population
started with abnormal Bhalla scores in 2007 and revealed
no statistical change until 2010 (Fig. 2c, Table 4). In
contrast, Loeve et al. [36] reported 2011 a slight but sig-
nificant deterioration of CT scores in children with mild CF
lung disease at intervals of two years.
The Bhalla score [31] used in the present study is based
on a 0e3 point system for each quality of lung impairment
that allows only rough assignment to different stages of
lung disease and may thus not be the optimal scoring sys-
tem for tracking mild lung disease over this relatively short
study duration of three years. In contrast, the Brody score
is a continuous variable on a scale of 0e100 [37]. But
although the Brody score is often used for investigating
early CF lung disease in younger patients [36,38], reference
data regarding upper limits of normal and intra- and inter-individual variability are not available. As an official
recommendation regarding a standard CT score for assess-
ing structural lung changes in young patients with CF is still
lacking, numerous CT scores and modifications of scores are
currently in use. The radiologists at the CF centre Innsbruck
have extensive clinical experiences with using the modified
Bhalla score in children and adults with CF for more than 10
years. Therefore the authors decided not to change this
practice for the purpose of the study.
However 30% (nZ 11) of the CT scores gained 1e2 points
in 2010 predominantly due to the reduction of mucus
plugging. This supports the view that abnormalities seen on
CT scans are potentially reversible to some extent.
Furthermore all patients with an improved CT score had an
improved LCI too.
3 out of 5 patients in whom the CT score worsened
during the study period, lost 2 points. An abnormal CT in
these patients was reflected by an abnormal LCI; while FEV1
and FEF75 were normal in 2007 and remained normal in two
of them until 2010. It is important to note that the clinical
course in these patients is characterised by lacking adher-
ence to therapy and several clinical complications such as
repeated and/or prolonged exacerbations.
MBW
Within-test repeatability of subsequent MBW tests for
calculating the LCI was good and comparable to published
data [18,34] using identical equipment.
In accordance with previous cross-sectional studies, the
LCI correlated significantly with the CT score [23,24] in both
2007 and 2010.
None of the patients with a normal LCI in 2007 developed
VI during the study period (Fig. 1a) and a normal LCI was
associated with no or minor changes (22 out of 25 points) on
CT.
In accordance with other paediatric CF populations
[13,14,18] only a small proportion (nZ 6) had a normal LCI
(and CT) in 2007. Therefore, calculation of positive and
negative predictive values in order to assess the predictive
value of the LCI for structural changes in later years as well
as direct comparison with the only prospective longitudinal
study evaluating the predictive value of the LCI [3] was not
appropriate. However, in 86% of the patients the LCI in 2007
was indicative for the presence or absence of structural
changes seen on CT in 2010 (Fig. 2a). This illustrates a
prognostic value of the LCI that was not seen for FEV1.
However, 3 out of 30 patients with an abnormal LCI in
2007 had a normal CT score in 2010 and 2 out of 6 patients
with a normal LCI in 2007 had an abnormal CT in 2010
(Fig. 2a). A similar distribution of results was observed
Figure 1 a: Course of LCI between 2007 and 2010 in n Z 6
patients with normal LCI in 2007. b: Course of LCI between
2007 and 2010 in n Z 22 patients with moderately increased
LCI in 2007. c: Course of LCI between 2007 and 2010 in n Z 8
patients with markedly increased LCI in 2007.
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trates, that MBW and chest CT are assessing different as-
pects of CF lung disease and should not replace each other.
While the latter detects structural lung changes (e.g. con-
solidations) that have not necessarily impact on lung
function (e.g. ventilation homogeneity), MBW detects
potentially reversible functional impairment (e.g. mucus
plugging) that is not necessarily related to structural
damage observed with CT scans. Therefore correlation
between LCI and CT score is expected to be less strong than
correlation within one of the methods [25]. To further in-
crease our understanding of early CF lung disease in rela-
tion to available diagnostic tools and to further prove the
predictive value of parameters used for monitoring, multi-
centre and longitudinal studies including larger numbers of
patients with normal LCI and CT will be necessary.
Over three years, LCI continuously improved in the ma-
jority of patients and the proportion of patients with an
abnormal LCI decreased markedly between 2007 and 2010
(Fig. 1aec). Mean LCI in 2010 for the group was significantly
lower than in 2007 and only slightly above the upper limit of
normal. However, more than 50% of the study population
still had an abnormal LCI at the end of the observation
period.
It may be argued that the yearly drop in LCI is explained
by changes in methodology during the study duration. It is
therefore important to note that all MBW tests were per-
formed with the same equipment, identical protocol,
software for data sampling and analysis and by the same
two investigators (SF and JE).
However the majority of patients (75%) started treat-
ment with hypertonic saline for preventive purposes be-
tween the first and the second test occasion. Even if the
present study design is not appropriate to investigate the
treatment effect of hypertonic saline on LCI, it seems likely
that the enhancement of the mucocilliar clearance
contributed to the observed drop in LCI for the group that
was most obvious in those individuals presenting the highest
LCI-results at study start (Fig. 1c).
The post-hoc analysis in patients with and patients
without treatment with hypertonic saline supports this
interpretation: LCI results were similar for the two groups
in 2007 (8.0 versus 8.1) and slightly different in 2008 (7.6
versus 8.2), 2009 (7.3 versus 8.2) and 2010 (7.0 versus 7.8)
but these differences were not significant. Improvement of
VI due to inhalation therapy with hypertonic saline has
previously been observed in two controlled intervention
studies in paediatric patients with CF and mild lung disease
(FEV1 >80% predicted at study start) where the authors
report a significant drop in mean LCI that was similar to the
present study population [20,22].
Another explanation for the observed improvement of VI
may be that any worsening in CT, lung function and/or
clinical status during the study period led to intensified
clinical management including medical treatments, phys-
iotherapy and additional consultations at the CF centre.
The clinicians at the CF centre in Innsbruck were not blin-
ded to the study results. Aiming to achieve optimal moti-
vation and adherence to the multidimensional treatment
regimen, CT and lung function were routinely discussed
with the patients and their families after each test
occasion.
Figure 2 a: Individual LCI 2007 versus individual CT-scores
2010. b: Individual FEV1-z 2007 versus individual CT-scores
2010. c: Individual CT-scores 2007 versus individual CT-scores
2010.
872 S.I. Fuchs et al.In 2011 Aurora et al. reported tracking of the LCI be-
tween preschool and early school age in CF [3]. In this
study, approximately one third had a significant deterio-
ration of LCI and approximately 16% a significant
improvement, while all but two LCI results remained
abnormal. Compared to the present study population, the
London patients had more severe lung disease despite
their younger age at study start (mean LCI >9 and inclu-
sion of patients with a reduced FEV1). However a recent
study tracking LCI and forced expired volume in
0.5 s (FEV0.5) during infancy reported stable but compared
to controls higher LCI results throughout the first year of
life [39].
Commonly, pulmonary changes in CF identified by CT
are thought to be mostly irreversible. We conclude from
our data, that partial reversibility of VI may be achieved in
patients with mild CF lung disease. It is likely, that
intensified clinical management and particularly
improvement of the mucociliar clearance, reduces mucus
plugging and air way wall thickening, resulting in more
homogenous ventilation. It is conceivable that ongoing
optimised mucociliar clearance leads to subsequent but in
comparison to LCI possibly delayed improvement of CT
scores.
Another aspect with regard to the role of MBW in
assessing progression of lung disease apparent from our
study is that the observed lung changes are small even over
the relatively long study period of three years. Longer
longitudinal studies are necessary to fully understand how
the LCI and other parameters of VI change over time, what
a significant change is and how this parameter may help to
predict prognosis.
In summary, this study indicates again that LCI derived
from MBW is sensitive for detecting and tracking pulmonary
changes in CF, particularly in young patients with mild lung
disease. Extended structural changes are unlikely if a
normal LCI is measured.
Therefore application of a chest CT may not be
necessary in the presence of a normal LCI. Measuring the
LCI longitudinally and prior to CT may help to reduce the
individual cumulative radiation burden within the CF
population. However, in a small proportion of patients,
changes observed with CT are not reflected by a change
in LCI, indicating that the two measures cannot be used
interchangeably.
We speculate, that routine measurements of the LCI may
lead to earlier intensified treatment and thus, slowing of
pulmonary changes.
Finally, we conclude that the LCI has the potential
to be used as surrogate marker for monitoring pro-
gression of CF lung disease and assessing the individual
effect of treatment in both, clinical care and research
settings.
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